Why a wakefulness drug is pharma's latest obsession

单集文稿 ...

• 00:03

  The Economist.

• 00:06

  Shailesh, I spend my day talking to AI companies

• 00:08

  who are convinced that they're going to overturn the entire pharmaceutical industry

• 00:13

  and cure all diseases in 10 years.

• 00:15

  You're our global business correspondent, you spend your day talking to pharma companies.

• 00:19

  And big pharma has had its own revolutions over the last few years, right?

• 00:23

  I'm thinking of GLP-1s here.

• 00:24

  The class of peptides that seem to have uses everywhere.

• 00:30

  Absolutely.

• 00:31

  That has been the big story in pharma over the last three to four years,

• 00:33

  which is the rise of GLP-1s.

• 00:35

  They started out as a treatment for diabetes,

• 00:37

  very quickly they realized it was really effective and safe in weight loss.

• 00:41

  It has turned out to be almost like an everything drug.

• 00:44

  And now pharma companies are hopeful

• 00:46

  that another molecule called orexin could have the potential to be the next blockbuster.

• 00:51

  And so I hadn't heard the word orexin before you said it.

• 00:55

  Should I have?

• 00:55

  How did you hear about it?

• 00:57

  I don't think you should have unless you were knee deep in these topics.

• 全部文稿